Beam Therapeutics Inc. (BEAM) Spending and interest coverage
- R&D / revenue · 12 months: Value 261.91%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 52.24%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 261.91% | Research and development expense / revenue. Period ending 2026-06-30. $408.66M ÷ $156.03M × 100 ≈ 261.91% |
| Stock-based compensation / revenue · 12 months | 52.24% | Share-based compensation / revenue. Period ending 2026-06-30. $81.52M ÷ $156.03M × 100 ≈ 52.24% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 408.66M USD | Research and Development Expense |
| Revenue | 156.03M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 81.52M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -378.02M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $408.66M | $156.03M | $81.52M | $-378.02M | (m) | 261.91% | 52.24% | (m) | (m) |
| 2026-03-31 | $415.33M | $164.01M | $86.61M | $-371.62M | (m) | 253.23% | 52.80% | (m) | (m) |
| 2025-12-31 | $409.62M | $139.74M | $94.24M | $-383.69M | (m) | 293.12% | 67.44% | (m) | (m) |
| 2025-09-30 | $411.79M | $55.70M | $104.01M | $-466.29M | (m) | 739.28% | 186.74% | (m) | (m) |
| 2025-06-30 | $396.28M | $60.27M | $110.83M | $-445.98M | (m) | 657.48% | 183.88% | (m) | (m) |
| 2025-03-31 | $381.56M | $63.58M | $118.06M | $-430.72M | (m) | 600.14% | 185.70% | (m) | (m) |
| 2024-12-31 | $367.56M | $63.52M | $120.66M | $-415.57M | (m) | 578.67% | 189.97% | (m) | (m) |
| 2024-09-30 | $406.19M | $349.64M | $113.06M | $-182.67M | (m) | 116.17% | 32.34% | (m) | (m) |
| 2024-06-30 | $411.99M | $352.57M | $109.34M | $-184.44M | (m) | 116.85% | 31.01% | (m) | (m) |
| 2024-03-31 | $422.55M | $360.91M | $104.01M | $-181.69M | (m) | 117.08% | 28.82% | (m) | (m) |
| 2023-12-31 | $437.38M | $377.71M | $98.65M | $-176.49M | (m) | 115.80% | 26.12% | (m) | (m) |
| 2023-09-30 | $383.64M | $81.55M | $98.53M | $-398.33M | (m) | 470.42% | 120.81% | (m) | (m) |
| 2023-06-30 | $368.88M | $80.16M | $94.90M | $-381.36M | (m) | 460.18% | 118.39% | (m) | (m) |
| 2023-03-31 | $345.83M | $76.70M | $90.20M | $-361.18M | (m) | 450.91% | 117.61% | (m) | (m) |
| 2022-12-31 | $311.59M | $60.92M | $84.32M | $-338.48M | (m) | 511.48% | 138.41% | (m) | (m) |
| 2022-09-30 | $322.03M | $91.95M | $77.32M | $-312.98M | (m) | 350.22% | 84.09% | (m) | (m) |
| 2022-06-30 | $291.37M | $76.92M | $68.08M | $-291.31M | (m) | 378.82% | 88.52% | (m) | (m) |
| 2022-03-31 | $262.39M | $60.27M | $56.96M | $-268.32M | (m) | 435.36% | 94.50% | (m) | (m) |
| 2021-12-31 | $387.09M | $51.84M | $43.57M | $-392.46M | (m) | 746.64% | 84.04% | (m) | (m) |
| 2021-09-30 | $322.76M | $781.00K | $34.88M | $-369.78M | (m) | 41326.12% | 4465.43% | (m) | (m) |
| 2021-06-30 | $297.96M | $24.00K | $24.92M | $-337.47M | (m) | 1241495.83% | 103829.17% | (m) | (m) |
| 2021-03-31 | $271.74M | $24.00K | $17.24M | $-304.78M | (m) | 1132233.33% | 71816.67% | (m) | (m) |
| 2020-12-31 | $103.18M | $24.00K | $15.38M | $-132.76M | (m) | 429912.50% | 64083.33% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $54.62M | $18.00K | $7.03M | $-75.15M | (m) | 303438.89% | 39044.44% | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |